Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy

• Main Authors: L. M. Soveri, A. Lamminmäki, U. A. Hänninen, M. Karhunen, P. Bono, P. Osterlund
• Format: Dataset
• Language: unknown
• Published: Taylor & Francis 2019
• Subjects: Medicine; Neuroscience; Biotechnology; Ecology; FOS Biological sciences; Immunology; FOS Clinical medicine; 69999 Biological Sciences not elsewhere classified; Cancer; Science Policy; Subarctic
• Online Access: https://dx.doi.org/10.6084/m9.figshare.7583348.v1; https://tandf.figshare.com/articles/Long-term_neuropathy_and_quality_of_life_in_colorectal_cancer_patients_treated_with_oxaliplatin_containing_adjuvant_chemotherapy/7583348/1

Background: Oxaliplatin, combined with capecitabine (CAPOX) or infused 5-fluorouracil (FOLFOX), is standard of care in the adjuvant treatment of colorectal cancer (CRC). Prospective data on prevalence of oxaliplatin induced acute and long-term neuropathy in a real-life patient population and its effects on quality of life (QOL) and survival is limited, and scarce in CAPOX versus FOLFOX treated, especially in a subarctic climate. Methods: One hundred forty-four adjuvant CRC patients (all 72 CAPOX cases and 72 matched FOLFOX controls) were analyzed regarding oxaliplatin induced sensory neuropathy, which was graded according to NCI-CTCAEv3.0. Ninety-two long-term survivors responded to the QOL (EORTC QLQ-C30) and Chemotherapy-Induced Peripheral Neuropathy (EORTC CIPN20) questionnaires and were interviewed regarding long-term neuropathy. Results: Acute neurotoxicity was present in 94% (136/144) during adjuvant therapy and there was a significant association between acute neurotoxicity and long-term neuropathy ( p p = .031), decreased role functioning ( p = .040), and more diarrhea ( p = .021) in QLQ-C30 items. There were no differences in acute neurotoxicity, long-term neuropathy, or in QOL between CAPOX and FOLFOX treated. Neuropathy showed no pattern of variation according to starting and stopping month or treatment during winter. Conclusions: Neuropathy following oxaliplatin containing adjuvant chemotherapy is present in two-thirds, years after cessation, and impairs some QOL scales. There is no difference in severity of acute or long-term neuropathy between CAPOX and FOLFOX treated and QOL is similar. No seasonal variation in neuropathy was noted.